MARKET WIREYahoo Finance • 14h ago
Agenus to Provide Third Quarter 2026 Financial Report and Development UpdateYahoo Finance report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
Why AGEN Stock dropped -3.53% Today — RQD Quant Desk Flash
$6.84 -3.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.78
Agenus Inc. (AGEN) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $320.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AGEN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Agenus Inc. (NASDAQ: AGEN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $6.84 (-3.53% 1D, market cap $320.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AGEN ranks #847 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AGEN compare to SCTX and ALEC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGEN carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SCTX (Scribe Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $330.2M) and ALEC (Alector Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M). Among the 5-stock peer group, AGEN leads on earnings multiple (N/A) while AGEN leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AGEN?
▼
Per AGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001098972), Agenus Inc. generated $114.2M in revenue (+10.4% YoY), -$3.1M in net income, and -$77.2M in free cash flow against $226.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.78 (-0.83%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AGEN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY AGEN SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (30% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (30% of score)
FRED Regime × Technicals: 54% of 52W Range • RSI-14 at 50 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$7.43-16.8% Next Q
38
Q2 (-2Q)Grade E$6.18-0.3% Next Q
35
Q3 (-1Q)Grade E$6.16+11% Next Q
33
CurrentGrade E$6.84-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AGEN Turnaround Squeeze
While AGEN currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.57) and Max Pain ($7.18) forces dealer call-delta covering toward $10.83.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AGEN Stock dropped -3.53% Today — RQD Quant Desk Flash
Agenus Inc. (AGEN) dropped -3.53% to $6.84, trading at 54% of its 52-week range ($2.71 – $10.31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 54% of its 52-week range ($2.71 – $10.31) with RSI-14 at 50 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $6.84 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 99.1% gross margin and $0 annual free cash flow.
Live AGEN Headlines & Catalysts
MARKET WIRESeeking Alpha • 17h ago
Agenus reports response rate in colon cancer trial (AGEN:NASDAQ)Seeking Alpha report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 20h ago
Chardan Capital maintains Buy rating on Agenus, $40 price targetTradingView report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 23h ago
Agenus (AGEN) Reports Promising Phase 2 UNICORN Trial Results in Colon CancerGuruFocus report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor ConferenceYahoo Finance report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
CATALYSTStock Titan • 1d ago
After six weeks of treatment, 83% had little or no cancer remaining at surgeryStock Titan report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Agenus (AGEN) Reports Promising Phase 2 Colon Cancer Trial ResulGuruFocus report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerYahoo Finance report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 18h ago
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon CancerLEXINGTON, Mass., November 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICO
CATALYSTYahoo • 8d ago
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026LEXINGTON, Mass., October 25, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an i
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AGEN)
- ✓Walkthrough of AGEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +70.15%📐 HORIZONTAL RANGE
2026-11-02O $7.13H $7.13L $6.84C $6.84VOL 625.5K
RES: $11.19SUP: $5.92SMA50: $7.57SMA200: $4.95
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AGEN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AGEN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AGEN)
Health Care Rank #847 of 1016
⚔️ SCTX vs AGEN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AGEN vs. SCTX, ALEC, XFOR, IRLA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Agenus Inc. (AGEN) ranks #847 by composite RQD confidence (30/100, grade E) and #514 by equity capitalization ($320.2M). Within this direct 5-issuer industry benchmark cohort, AGEN leads on earnings valuation at N/A trailing P/E, while AGEN leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCTX currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with AGEN at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AGEN
ACTIVE
Agenus Inc. | E | 30/100 | — | 96.0% | -35.0% | -3.53% | $320.2M | Benchmark Subject |
| SCTX Scribe Therapeutics Inc. | D | 44/100 | — | — | — | -11.58% | $330.2M | /sctx-vs-agen → |
| ALEC Alector Inc. | E | 33/100 | — | — | -35.0% | -1.34% | $332.1M | /alec-vs-agen → |
| XFOR X4 Pharmaceuticals Inc. | E | 29/100 | — | 83.6% | -35.0% | -0.30% | $333.1M | /xfor-vs-agen → |
| IRLA IRulya Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +4.21% | $342.8M | /irla-vs-agen → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001098972In its most recent audited fiscal period (FY2025, filed 2025-12-31), Agenus Inc. (AGEN) reported GAAP revenue of $114.2M (+10.4% vs. FY2024 revenue of $103.5M , and -26.9% cumulative change since FY2023) , GAAP net income of -$3.1M, operating cash flow of -$77.2M, and free cash flow of -$77.2M (+51.4% YoY). On the balance sheet, AGEN closed FY2025 with $226.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $114.2M | -$3.1M | -$77.2M | -$77.2M | $226.8M | $0 |
| FY2024 (FY) | 2024-12-31 | $103.5M | -$232.3M | -$158.3M | -$158.9M | $226.3M | $30.5M |
| FY2023 (FY) | 2023-12-31 | $156.3M | -$257.4M | -$224.2M | -$224.2M | — | — |
3. AGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Agenus Inc. (NASDAQ: AGEN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $6.84 (-3.53% 1D, market cap $320.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AGEN ranks #847 in composite RQD confidence.
How does AGEN compare to SCTX and ALEC in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGEN carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SCTX (Scribe Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $330.2M) and ALEC (Alector Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M). Among the 5-stock peer group, AGEN leads on earnings multiple (N/A) while AGEN leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AGEN?
Per AGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001098972), Agenus Inc. generated $114.2M in revenue (+10.4% YoY), -$3.1M in net income, and -$77.2M in free cash flow against $226.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AGEN trading relative to its 50-day, 200-day, and 52-week technical levels?
AGEN last traded at $6.84 (-3.53% on volume of 564,617 shares), positioning the stock -9.64% below its 50-day simple moving average ($7.57) and +38.18% above its 200-day simple moving average ($4.95). Across its 52-week range of $2.71 to $10.31, AGEN sits at the 54.3% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.99 to $7.69).
AGEN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AGEN stock moving today?
Why AGEN Stock dropped -3.53% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AGEN — Agenus Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:28Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AGEN scores 30 out of 100 and carries a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -24.11%. For a prospective investor, the cash engine is the weakest link: the business is consuming capital rather than generating it, so any valuation must rest on future cash flows that the reported data does not yet show.
- Whale 13F Flow: 9 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, indicating limited institutional conviction in the source data. Investor implication: the absence of strong smart-money support removes one potential source of price stabilization.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar after the cash engine, signaling weak insider-level confidence.
- Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity. The stock moves with the market but offers no defensive cushion.
- Forensic Balance Sheet: 5 / 20. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. These figures place the balance sheet in a weak-to-moderate forensic posture.
Valuation tradeoffs: per the market data, P/E, forward P/E, EV/EBITDA, and EPS are not available in source data, so earnings-based valuation cannot be established. Upside drivers the data points toward are the 83% figure and colon-cancer trial response headlines in the news wire, but their financial translation is not quantified in the source data. Overall, the pillar profile describes a high-risk, cash-consuming equity with limited institutional and insider support.
Business
Agenus Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the company profile. Per the profile, the company has a market capitalization of $0.3B. The source data does not describe specific products, customers, or revenue model beyond the reported financials and news headlines referencing clinical trial results.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $114.2M | $-20.2M | $-3.1M | N/A | $-77.2M | $3.0M | $0.0M |
| FY 2024 | $103.5M | $-120.5M | $-232.3M | N/A | $-158.9M | $40.4M | $30.5M |
| FY 2023 | $156.3M | $-159.5M | $-257.4M | N/A | $-224.2M | N/A | N/A |
Per the SEC financials, revenue declined from $156.3M in FY 2023 to $114.2M in FY 2025, while operating losses narrowed from $-159.5M to $-20.2M. Per the market data, gross margin is 96%, operating margin is -17.7%, and net margin is -2.7%. ROIC is -35% and FCF yield is -24.11%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Per the SEC financials, FY 2025 debt is reported as $0.0M, down from $30.5M in FY 2024.
Recent Catalysts & News Wire Analysis
Per the recent news wire, the headlines include a Q3 2026 financial report and development update announcement, a reported response rate in a colon cancer trial, a Chardan Capital Buy rating with a $40 price target, a Phase 2 UNICORN trial results report in colon cancer, and participation in Chardan's 10th Annual Healthcare Investor Conference. One item is flagged as a CATALYST (green signal) referencing a result stating that after six weeks of treatment, 83% had little or no cancer remaining at surgery. The remaining items carry a YELLOW light, indicating market-wire coverage rather than confirmed catalyst status. Per the butterfly supply-chain graph, no proprietary signals or supply-chain links are available.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be mapped from the source data. Sector correlation is limited to the Health Care / Biological Products classification. Investors should watch clinical-trial readouts in colon cancer as the primary second-order driver, since the news wire ties the stock's attention to those results, though the source data does not quantify the dependency.
Open Questions
- What is the company's cash runway given FY 2025 cash of $3.0M against FCF of $-77.2M?
- Are the FY 2023 cash and debt figures available, and what drove the change in debt between FY 2024 and FY 2025?
- What portion of the colon-cancer trial results is statistically significant, and how do they translate to revenue?
- What are the EPS, forward P/E, and EV/EBITDA figures needed to anchor a valuation?
- Who are the institutional and insider holders, given that holder and analyst data are unavailable?
AGEN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Agenus Inc. (AGEN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 14h ago
Agenus to Provide Third Quarter 2026 Financial Report and Development Update Yahoo Finance report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 17h ago
Agenus reports response rate in colon cancer trial (AGEN:NASDAQ) Seeking Alpha report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 20h ago
Chardan Capital maintains Buy rating on Agenus, $40 price target TradingView report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 23h ago
Agenus (AGEN) Reports Promising Phase 2 UNICORN Trial Results in Colon Cancer GuruFocus report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference Yahoo Finance report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stock Titan • 1d ago
After six weeks of treatment, 83% had little or no cancer remaining at surgery Stock Titan report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Agenus (AGEN) Reports Promising Phase 2 Colon Cancer Trial Resul GuruFocus report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer Yahoo Finance report covering Agenus Inc. (AGEN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AGEN Bull vs. Bear Conversation Board — What's Your Call at $6.84?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AGEN 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $6.24 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AGEN (E • RQD 30/100) a Buy at $7.09?
Welcome to the AGEN (Agenus Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $5.46 (-23.0%)
Spot @ $7.09 Pump the brakes on AGEN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AGEN, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Agenus Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $8.93 (+26.0%)
Spot @ $7.09 AGEN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AGEN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $7.09 (52-wk range $2.71 - $10.31), any beat on forward guidance forces shorts and underweight funds to chase.